{"id":2223,"date":"2026-06-09T23:00:00","date_gmt":"2026-06-10T02:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2223"},"modified":"2026-06-09T23:00:00","modified_gmt":"2026-06-10T02:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-pancreatica-whipple-distal-total-folfirinox-gemcitabina-nab","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-pancreatica-whipple-distal-total-folfirinox-gemcitabina-nab\/","title":{"rendered":"PGRSS pancre\u00e1tica: Whipple, FOLFIRINOX"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica pancre\u00e1tica que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica pancre\u00e1tica<\/strong> + DPC duodenopancreatectomia Whipple cabe\u00e7a<\/strong> + PD distal corpo+cauda<\/strong> + PT total + esplenectomia + linfadenectomia padr\u00e3o<\/strong> + FOLFIRINOX modificado mFOLFIRINOX adjuvante PRODIGE-24<\/strong> + gemcitabina + nab-paclitaxel Abraxane MPACT<\/strong> + olaparib Lynparza BRCA1\/2<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (adenoCa ductal pancre\u00e1tico PDAC + IPMN intraductal papillary + MCN mucinous cystic + PNET pancreatic neuroendocrine + acinar cell carcinoma) + Grupo A4 (linfa peripancre\u00e1tica + porta hepatis + tronco cel\u00edaco + AMS art\u00e9ria mesent\u00e9rica superior + para-a\u00f3rtica) + Grupo C (Iridium-192 brachy raro + Lu-177 DOTATATE Lutathera PNET + Y-90 SIRT) + Grupo E (perfuro bi\u00f3psia EUS-FNA + agulha core) + Lista C5 (FOLFIRINOX 5-FU+leucovorin+irinotecan+oxaliplatina + gemcitabina Gemzar + nab-paclitaxel Abraxane + olaparib Lynparza + erlotinib Tarceva + sotorasib Lumakras KRAS-G12C + adagrasib Krazati). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + Whipple complexo<\/strong> + subdimensionam FOLFIRINOX Lista C5<\/strong> + perdem rastreabilidade tumor p\u00e2ncreas<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS pancre\u00e1tica opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (PDAC adenoCa ductal 85% + IPMN 10% + MCN 1-2% + PNET 1-2% + acinar cell 1%), A4 (linfadenectomia padr\u00e3o peripancre\u00e1tica + porta hepatis + tronco cel\u00edaco + AMS + para-a\u00f3rtica), C (Lu-177 DOTATATE Lutathera PNET + Y-90 SIRT met\u00e1stase hep\u00e1tica + Iridium-192 raro), E (EUS-FNA endoscopic ultrasound fine-needle aspiration + bi\u00f3psia core ultrassom-guiada + brush ERCP), Lista C5 (FOLFIRINOX adjuvante PRODIGE-24 + gem+nab-paclitaxel MPACT 1L metast\u00e1tico + olaparib Lynparza BRCA + erlotinib Tarceva + sotorasib Lumakras KRAS).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica pancre\u00e1tica, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos pancre\u00e1ticos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS pancre\u00e1tica tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 PDAC+IPMN+PNET<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nDuctal 85%+IPMN+PNET<\/td>\n<\/tr>\n
A4 linfa perip\u00e2ncreas<\/td>\n4-11 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nPorta hepatis+cel\u00edaco<\/td>\n<\/tr>\n
C Lu-177+Y-90+Ir-192<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nDOTATATE+SIRT<\/td>\n<\/tr>\n
E EUS-FNA+core<\/td>\n0,4-1,2 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nEndosc\u00f3pico+ultrassom<\/td>\n<\/tr>\n
FOLFIRINOX+gem Lista C5<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nmFOLFIRINOX+nab-pac<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,4-31,2 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica pancre\u00e1tica m\u00e9dia porte.<\/p>\n

A1 PDAC + IPMN + MCN + PNET + acinar cell: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS pancre\u00e1tica \u00e9 A1. Padr\u00e3o setorial inclui (a) PDAC adenoCa ductal pancre\u00e1tico 85%<\/strong> com cabe\u00e7a 60-70% + corpo 15% + cauda 15% + sobrevida 5y <10% + KRAS muta\u00e7\u00e3o 95% + TP53 75% + CDKN2A 90% + SMAD4 50%; (b) IPMN intraductal papillary mucinous neoplasm 10%<\/strong> com main duct + branch duct + mixed type + Sendai+Fukuoka crit\u00e9rios cirurgia + worrisome features + high-risk stigmata; (c) MCN mucinous cystic neoplasm 1-2%<\/strong> com mulher meia-idade + corpo+cauda + ovariano-like stroma + risco maligniza\u00e7\u00e3o; (d) PNET pancreatic neuroendocrine tumor 1-2%<\/strong> com funcional insulinoma+gastrinoma+VIPoma+glucagonoma+somatostatinoma + n\u00e3o-funcional + Ki-67 G1<3%\/G2 3-20%\/G3>20% + MEN-1 multiple endocrine neoplasia; (e) estadiamento TNM 8\u00aa edi\u00e7\u00e3o<\/strong> Tis + T1 \u22642cm + T2 2-4cm + T3 >4cm + T4 invade tronco cel\u00edaco\/AMS + N0\/N1\/N2 + M0\/M1.<\/p>\n

Cl\u00ednica com A1 pancre\u00e1tica madura garante margem R0<\/strong> + previne recidiva regional<\/strong> + otimiza estadiamento TNM 8\u00aa<\/strong>. Como discutimos no post sobre vias biliares<\/a>, A1 \u00e9 a base.<\/p>\n

A4 Whipple DPC + distal + total + linfadenectomia padr\u00e3o: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) DPC duodenopancreatectomia Whipple<\/strong> com cabe\u00e7a p\u00e2ncreas + duodeno + 1\u00aa al\u00e7a jejunal + ves\u00edcula+CBD comum + est\u00f4mago distal antrectomia + reconstru\u00e7\u00e3o pancreaticojejunostomia + col\u00e9doco-jejunostomia + gastrojejunostomia; (b) PPPD pylorus-preserving pancreaticoduodenectomy<\/strong> com preservar piloro Traverso-Longmire + reduz dumping + compar\u00e1vel oncol\u00f3gico; (c) PD distal pancreatectomia<\/strong> corpo+cauda + esplenectomia rotineira preservar ba\u00e7o RAMPS Radical Antegrade Modular Pancreatosplenectomy + mobiliza\u00e7\u00e3o Kocher; (d) PT total<\/strong> com remo\u00e7\u00e3o completa p\u00e2ncreas + duodeno + esplenectomia + colecistectomia + diabetes p\u00f3s-cir\u00fargico + insulina vital + esteatorreia enzima; (e) linfadenectomia padr\u00e3o<\/strong> com peripancre\u00e1tica + porta hepatis 8 + 12 + 13 + 14 + tronco cel\u00edaco 9 + AMS art\u00e9ria mesent\u00e9rica superior 14 + para-a\u00f3rtica seletiva + 15-25 LN dissecados padr\u00e3o ouro.<\/p>\n

Cl\u00ednica com Whipple+PD+PT madura escala R0 60-80%<\/strong> + previne f\u00edstula pancre\u00e1tica POPF 10-30%<\/strong> + gerencia diabetes p\u00f3s-PT<\/strong>. Conex\u00e3o com hospital especializado<\/a>.<\/p>\n

FOLFIRINOX + gem+nab-paclitaxel + olaparib + Lu-177 DOTATATE: o est\u00e1gio quimio+targeted+radio<\/h2>\n

A terceira camada \u00e9 quimio+targeted+PRRT. Padr\u00e3o setorial inclui (a) FOLFIRINOX adjuvante PRODIGE-24 modificado mFOLFIRINOX<\/strong> 5-FU bolus 400 mg\/m\u00b2 + 5-FU IC 2.400 mg\/m\u00b2 + leucovorin 400 mg\/m\u00b2 + irinotecan 150 mg\/m\u00b2 + oxaliplatina 85 mg\/m\u00b2 + 12 ciclos q2w + ECOG 0-1; (b) gem+nab-paclitaxel Abraxane MPACT<\/strong> 1L metast\u00e1tico + gemcitabina 1.000 mg\/m\u00b2 + nab-paclitaxel 125 mg\/m\u00b2 q4w D1+8+15 + neutropenia+neuropatia; (c) olaparib Lynparza BRCA1\/2 mutated<\/strong> POLO trial maintenance metast\u00e1tico + 300mg BID + tucatinib n\u00e3o-aplic\u00e1vel pancre\u00e1tico + sotorasib Lumakras KRAS-G12C 8% PDAC + adagrasib Krazati; (d) Lu-177 DOTATATE Lutathera PRRT NET<\/strong> Novartis 7,4 GBq IV q8w \u00d7 4 doses NETTER-1+NETTER-2 + somatostatin receptor SSTR2\/5+; (e) descarte FOLFIRINOX+gem+olaparib+Lu-177<\/strong> com Lista C5 5-FU+leuco+irinotecan+oxali+gemcitabina+nab-pacli+olaparib+sotorasib+adagrasib + Lu-177 decaimento 6,7d + IPEN\/CNEN-NN-3.05 + saco amarelo+vermelho.<\/p>\n

Cl\u00ednica com FOLFIRINOX+gem+olaparib+Lu-177 madura escala OS PRODIGE-24 54,4 meses adjuvante<\/strong> + escala OS olaparib POLO 7,4 meses progress\u00e3o livre<\/strong> + escala Lu-177 PRRT PNET 65 meses OS<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade pancre\u00e1tica<\/h2>\n

Cl\u00ednica pancre\u00e1tica s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.500-28.000<\/strong> mas perda de A4+C+E+FOLFIRINOX.<\/p>\n

Cl\u00ednica pancre\u00e1tica A1 + A4 + FOLFIRINOX.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura cirurgia + linfa + adjuvante.<\/p>\n

Cl\u00ednica pancre\u00e1tica 5 fluxos completos.<\/strong> A1+A4+C+E+FOLFIRINOX + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 42.000-98.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa pancre\u00e1tica + Whipple R0 + FOLFIRINOX OS 54,4 meses.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica pancre\u00e1tica<\/h2>\n

O primeiro \u00e9 a subdimensionamento FOLFIRINOX Lista C5<\/strong>. Sem segrega\u00e7\u00e3o 5-FU+leuco+irinotecan+oxaliplatina+gemcitabina+nab-pacli+olaparib + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 PDAC + A4 linfa perip\u00e2ncreas<\/strong>. Confunde rastreabilidade tumor + impossibilita linfadenectomia padronizada porta hepatis+cel\u00edaco+AMS 15-25 LN + risco subestadiamento.<\/p>\n

O terceiro \u00e9 a falta de protocolo Whipple + manejo POPF f\u00edstula pancre\u00e1tica<\/strong>. Sem rastreabilidade pancreaticojejunostomia + dreno + ISGPS POPF cl\u00e1ssica + interven\u00e7\u00e3o radiol\u00f3gica = risco POPF Grade C + sepse + risco mortalidade 30d.<\/p>\n

A regula\u00e7\u00e3o de PGRSS pancre\u00e1tica no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer P\u00e2ncreas<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS pancre\u00e1tica 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 PDAC adenoCa ductal 85% KRAS+TP53+CDKN2A+SMAD4+IPMN main+branch+mixed+Sendai+Fukuoka+MCN ovariano-like+PNET insulinoma+gastrinoma+VIPoma+glucagonoma+somatostatinoma+Ki-67 G1\/G2\/G3+MEN-1+CID C25+TNM 8\u00aa, A4 DPC Whipple cabe\u00e7a+duodeno+CBD+colecistectomia+pancreaticojejunostomia+col\u00e9doco-jejunostomia+gastrojejunostomia+PPPD Traverso-Longmire+PD distal RAMPS+esplenectomia+PT total+diabetes+esteatorreia+linfadenectomia padr\u00e3o porta hepatis 8+12+13+14+cel\u00edaco 9+AMS 14+para-a\u00f3rtica 15-25 LN+POPF 10-30% ISGPS, C Lu-177 DOTATATE Lutathera Novartis 7,4 GBq\u00d74 NETTER-1\/2+Y-90 SIRT met\u00e1stase hep\u00e1tica+Iridium-192 raro+CNEN-NN-3.05, E EUS-FNA endoscopic ultrasound+core+brush ERCP, mFOLFIRINOX adjuvante PRODIGE-24 OS 54,4m+gem+nab-paclitaxel Abraxane MPACT 1L+olaparib Lynparza POLO BRCA1\/2 7,4m PFS+sotorasib Lumakras+adagrasib Krazati KRAS-G12C+erlotinib Tarceva Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia pancre\u00e1tica: Whipple + distal + FOLFIRINOX + gem. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2222,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,2872,3056,2871],"class_list":["post-2223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-folfirinox","tag-pancreatica","tag-whipple"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2223"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2223\/revisions"}],"predecessor-version":[{"id":4335,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2223\/revisions\/4335"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2222"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}